Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Antihemophilic Factor Drug Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Antihemophilic Factor Drug Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 250 IU
      • 1.3.3 500 IU
      • 1.3.4 1000 IU
      • 1.3.5 1500 IU
      • 1.3.6 2000 IU
      • 1.3.7 3000 IU
      • 1.3.8 4000 IU
      • 1.3.9 Other potencies
    • 1.4 Market Segment by Application
      • 1.4.1 Global Antihemophilic Factor Drug Market Share by Application (2019-2025)
      • 1.4.2 Adult
      • 1.4.3 Pediatric
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Antihemophilic Factor Drug Market Size
      • 2.1.1 Global Antihemophilic Factor Drug Revenue 2014-2025
      • 2.1.2 Global Antihemophilic Factor Drug Sales 2014-2025
    • 2.2 Antihemophilic Factor Drug Growth Rate by Regions
      • 2.2.1 Global Antihemophilic Factor Drug Sales by Regions 2014-2019
      • 2.2.2 Global Antihemophilic Factor Drug Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Antihemophilic Factor Drug Sales by Manufacturers
      • 3.1.1 Antihemophilic Factor Drug Sales by Manufacturers 2014-2019
      • 3.1.2 Antihemophilic Factor Drug Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Antihemophilic Factor Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Antihemophilic Factor Drug Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Antihemophilic Factor Drug Market Concentration Ratio (CR5 and HHI)
    • 3.3 Antihemophilic Factor Drug Price by Manufacturers
    • 3.4 Key Manufacturers Antihemophilic Factor Drug Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Antihemophilic Factor Drug Market
    • 3.6 Key Manufacturers Antihemophilic Factor Drug Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 250 IU Sales and Revenue (2014-2019)
      • 4.1.2 500 IU Sales and Revenue (2014-2019)
      • 4.1.3 1000 IU Sales and Revenue (2014-2019)
      • 4.1.4 1500 IU Sales and Revenue (2014-2019)
      • 4.1.5 2000 IU Sales and Revenue (2014-2019)
      • 4.1.6 3000 IU Sales and Revenue (2014-2019)
      • 4.1.7 4000 IU Sales and Revenue (2014-2019)
      • 4.1.8 Other potencies Sales and Revenue (2014-2019)
    • 4.2 Global Antihemophilic Factor Drug Sales Market Share by Type
    • 4.3 Global Antihemophilic Factor Drug Revenue Market Share by Type
    • 4.4 Antihemophilic Factor Drug Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Antihemophilic Factor Drug Sales by Application

    6 United States

    • 6.1 United States Antihemophilic Factor Drug Breakdown Data by Company
    • 6.2 United States Antihemophilic Factor Drug Breakdown Data by Type
    • 6.3 United States Antihemophilic Factor Drug Breakdown Data by Application

    7 European Union

    • 7.1 European Union Antihemophilic Factor Drug Breakdown Data by Company
    • 7.2 European Union Antihemophilic Factor Drug Breakdown Data by Type
    • 7.3 European Union Antihemophilic Factor Drug Breakdown Data by Application

    8 China

    • 8.1 China Antihemophilic Factor Drug Breakdown Data by Company
    • 8.2 China Antihemophilic Factor Drug Breakdown Data by Type
    • 8.3 China Antihemophilic Factor Drug Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Antihemophilic Factor Drug Breakdown Data by Company
    • 9.2 Rest of World Antihemophilic Factor Drug Breakdown Data by Type
    • 9.3 Rest of World Antihemophilic Factor Drug Breakdown Data by Application
    • 9.4 Rest of World Antihemophilic Factor Drug Breakdown Data by Countries
      • 9.4.1 Rest of World Antihemophilic Factor Drug Sales by Countries
      • 9.4.2 Rest of World Antihemophilic Factor Drug Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Bayer
      • 10.1.1 Bayer Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Antihemophilic Factor Drug
      • 10.1.4 Antihemophilic Factor Drug Product Introduction
      • 10.1.5 Bayer Recent Development
    • 10.2 Shire
      • 10.2.1 Shire Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Antihemophilic Factor Drug
      • 10.2.4 Antihemophilic Factor Drug Product Introduction
      • 10.2.5 Shire Recent Development
    • 10.3 Novo Nordisk
      • 10.3.1 Novo Nordisk Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Antihemophilic Factor Drug
      • 10.3.4 Antihemophilic Factor Drug Product Introduction
      • 10.3.5 Novo Nordisk Recent Development
    • 10.4 Pfizer
      • 10.4.1 Pfizer Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Antihemophilic Factor Drug
      • 10.4.4 Antihemophilic Factor Drug Product Introduction
      • 10.4.5 Pfizer Recent Development
    • 10.5 Grifols
      • 10.5.1 Grifols Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Antihemophilic Factor Drug
      • 10.5.4 Antihemophilic Factor Drug Product Introduction
      • 10.5.5 Grifols Recent Development
    • 10.6 CSL Behring
      • 10.6.1 CSL Behring Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Antihemophilic Factor Drug
      • 10.6.4 Antihemophilic Factor Drug Product Introduction
      • 10.6.5 CSL Behring Recent Development
    • 10.7 Sanofi
      • 10.7.1 Sanofi Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Antihemophilic Factor Drug
      • 10.7.4 Antihemophilic Factor Drug Product Introduction
      • 10.7.5 Sanofi Recent Development
    • 10.8 Cigna
      • 10.8.1 Cigna Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Antihemophilic Factor Drug
      • 10.8.4 Antihemophilic Factor Drug Product Introduction
      • 10.8.5 Cigna Recent Development
    • 10.9 Octapharma
      • 10.9.1 Octapharma Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Antihemophilic Factor Drug
      • 10.9.4 Antihemophilic Factor Drug Product Introduction
      • 10.9.5 Octapharma Recent Development
    • 10.10 GC Pharma
      • 10.10.1 GC Pharma Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Antihemophilic Factor Drug
      • 10.10.4 Antihemophilic Factor Drug Product Introduction
      • 10.10.5 GC Pharma Recent Development
    • 10.11 Hualan Biological Engineering
    • 10.12 Shanghai RAAS blood products

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Antihemophilic Factor Drug Sales Channels
      • 11.2.2 Antihemophilic Factor Drug Distributors
    • 11.3 Antihemophilic Factor Drug Customers

    12 Market Forecast

    • 12.1 Global Antihemophilic Factor Drug Sales and Revenue Forecast 2019-2025
    • 12.2 Global Antihemophilic Factor Drug Sales Forecast by Type
    • 12.3 Global Antihemophilic Factor Drug Sales Forecast by Application
    • 12.4 Antihemophilic Factor Drug Forecast by Regions
      • 12.4.1 Global Antihemophilic Factor Drug Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Antihemophilic Factor Drug Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Antihemophilic Factor Drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to prevent bleeding.
      In 2019, the market size of Antihemophilic Factor Drug is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Antihemophilic Factor Drug.

      This report studies the global market size of Antihemophilic Factor Drug, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Antihemophilic Factor Drug sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Bayer
      Shire
      Novo Nordisk
      Pfizer
      Grifols
      CSL Behring
      Sanofi
      Cigna
      Octapharma
      GC Pharma
      Hualan Biological Engineering
      Shanghai RAAS blood products

      Market Segment by Product Type
      250 IU
      500 IU
      1000 IU
      1500 IU
      2000 IU
      3000 IU
      4000 IU
      Other potencies

      Market Segment by Application
      Adult
      Pediatric

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Antihemophilic Factor Drug status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Antihemophilic Factor Drug manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Antihemophilic Factor Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now